- Kuida® introduced as first Colombian mass-market CBD
Cosmeceutical brand at Cosmoprof
- Event attracts up to 200,000 global retail buyers (Source:
BolognaFiere Group )
- Khiron Skin Unit Director to speak on CBD-based cosmetics
expert panel
- Global skincare market expected to reach US$131 Billion in 2019
TORONTO, March 5, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), a vertically integrated cannabis leader with core
operations in Latin America,
announced today that the Company will participate in Cosmoprof
Worldwide Bologna, taking place March
14-17 in Bologna, Italy.
Recognized as the largest and most important event in the beauty
buyers' calendar, this event brings the Company's
Kuida® cosmeceutical portfolio to a global network of retail
buyers and distributors.
Andres Galofre, Co-founder and VP
Business Development, Khiron Life Sciences Corp., states, "Our
participation in Cosmoprof Worldwide Bologna marks an important
milestone for Khiron as we bring the Kuida® brand to the
global market for the first time. As well, we will be educating
beauty buyers about cannabis legislation in their jurisdiction as
it applies to CBD-based cosmeceuticals, and increase awareness of
the market potential in this fast developing category."
Kuida®, the first consumer brand for Khiron's wellness unit,
brings the benefits of cannabidol (CBD) to a comprehensive
portfolio of skin and body care products for women. Launched
in Colombia in October 2018 through retail,
wholesale and online channels, Kuida® will now target the
global skincare market which, according to Euromonitor
International is expected to reach US$131
Billion in 2019.
Elsa Navarro, Skin Unit Director,
Khiron life Sciences Corp., states "CBD-based products are rapidly
taking centre stage on the global skincare market. With our proven
product development and marketing experience it is important for
Kuida® to participate in the industry discussion on product
innovation, consumer education, legislation, distribution and
marketing, in order to assist retail buyers in making informed
buying decisions."
Juan Carlos Castro, Director of
Cosmetics and Cleanliness Industry at ANDI, the National
Business Association of Colombia,
commented, "Global trends led by consumers and manufacturers have
created opportunity for new technologies and ingredients that can
bring wellness benefits, including through the use of cannabis.
Khiron has recognized this opportunity and is leading the path in
Latin America through the
development of their Kuida® consumer brand."
Visit Khiron at Cosmoprof Worldwide Bologna: Hall 14,
Extraordinary Gallery booth 26
About BolognaFiere Group
BolognaFiere is one the leading International exhibition
organizers and one of the most advanced exhibition centres
worldwide.
BolognaFiere Group manages three exhibition centres (Bologna,
Modena, and Ferrara) with over 75 outstanding exhibitions in
Italy and abroad; BolognaFiere
Group consists of several companies than offer an extensive range
of events and provide businesses with all of the promotion and
specialized services they need to successfully participate in every
exhibition. For more information on BolognaFiere Group visit
www.bolognafiere.it
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
Cautionary Notes
Market and Industry Data
This press release contains market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, the
Company has not independently verified any of the data from
third-party sources referred to in this press release, or analyzed
or verified the underlying studies or surveys relied upon or
referred to by such sources, or ascertained the underlying economic
assumptions relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable Canadian securities legislation. All information
contained herein that is not historical in nature may constitute
forward-looking information. Forward-looking statements may be
identified by statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements.
Khiron undertakes no obligation to comment analyses, expectations
or statements made by third-parties in respect of Khiron, its
securities, or financial or operating results (as applicable).
Although Khiron believes that the expectations reflected in
forward-looking statements in this press release are reasonable,
such forward-looking statement has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Khiron's control, including the risk
factors discussed in Khiron's Annual Information Form which is
available on Khiron's SEDAR profile at www.sedar.com. The
forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE Khiron Life Sciences Corp.